Editor’s note

With little known Lee Pharma filing India's third compulsory licensing (CL), legal eagles and everyone interested or connected to…

When governments have to weigh public health against IP issues, LDCs and developing countries really have no choice but to plug…

Two reports, released in early June, have both good news and bad news for the pharma industry in India

Just as 2015 is a make or break year for PM Modi, this will be a decisive year for the pharma sector as well Now that the…

India once again made it to the Priority Watch list of the 2015 USTR Special 301 Report, but this year, the reaction from India’s…

As Prime Minister Modi completes a year in office this May, there will no doubt be many lists of this government’s achievements…

As we settle into FY2016, it is worth taking a quick look at some of the earning previews of the last quarter

Success hinges on the company getting its GMP right and surviving the glare of regulatory scrutiny

Finance Minister Arun Jaitley’s first Union Budget had nothing special for the pharmaceutical industry

As in previous years, we mark this Women's Day with a cover story section devoted to women's health issue

The draft National IPR policy, unveiled last December by the Department of Industrial Policy & Promotion (DIPP), has already…

While we are urged to look beyond the sticky issues, one cannot overlook the final impact of decisions on India's IPR policy

CDSCO's planned 'harmonisation of recruitment rules' is sure to resurrect this debate

As the adage goes, look before you leap

Now that India’s competition watch dog, the Competition Commission of India (CCI) has given its nod to Sun Pharma’s acquisition of…

Sometimes, the more things change, the more they remain the same. Express Pharma Pulse was launched in December 1994. Change was…

As we discussed themes for Express Pharma’s 20th Anniversary series which kicks off with the December 1-15 issue, we were struck…

Why are pharma companies in India still falling foul of overseas regulators?